Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model
- PMID: 17355635
- PMCID: PMC1831483
- DOI: 10.1186/1476-4598-6-21
Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model
Abstract
Background: microRNAs (miRNAs) are a group of non-coding single stranded RNAs measuring approximately 22 nucleotides in length that have been found to control cell growth, differentiation and apoptosis. They negatively regulate target genes and have recently been implicated in tumourigenesis. Furthermore, miRNA expression profiling correlates with various cancers, with these genes thought to act as both tumour suppressors and oncogenes. Recently, a point mutation in the BRAF gene leading to a V600E substitution has been identified as the most common genetic change in papillary thyroid carcinoma (PTC) occurring in 29-69% of cases. This mutation leads to aberrant MAPK activation that is implicated in tumourigenesis.
Aim: The aim of this study was to identify the effect that BRAF oncogene has on post-transcriptional regulation in PTC by using microRNA analysis.
Results: A unique miRNA expression signature differentiated between PTC cell lines with BRAF mutations and a normal thyroid cell line. 15 miRNAs were found to be upregulated and 23 miRNAs were downregulated. Several of these up/down regulated miRNAs may be involved in PTC pathogenesis. miRNA profiling will assist in the elucidation of disease pathogenesis and identification biomarkers and targets.
Figures
Similar articles
-
Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model.Mol Cancer. 2006 Dec 11;5:70. doi: 10.1186/1476-4598-5-70. Mol Cancer. 2006. PMID: 17156473 Free PMC article.
-
Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma.Horm Metab Res. 2009 Jun;41(6):482-7. doi: 10.1055/s-0029-1215558. Epub 2009 Apr 15. Horm Metab Res. 2009. PMID: 19370505
-
Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma.Histopathology. 2010 Apr;56(5):632-40. doi: 10.1111/j.1365-2559.2010.03526.x. Histopathology. 2010. PMID: 20459574
-
BRAF mutations in papillary thyroid carcinoma.Endocr Regul. 2006 Dec;40(4):129-38. Endocr Regul. 2006. PMID: 17201587 Review.
-
Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.Cancer. 2005 Jun 1;103(11):2261-8. doi: 10.1002/cncr.21073. Cancer. 2005. PMID: 15880523 Review.
Cited by
-
MEAHNE: miRNA-Disease Association Prediction Based on Semantic Information in a Heterogeneous Network.Life (Basel). 2022 Oct 11;12(10):1578. doi: 10.3390/life12101578. Life (Basel). 2022. PMID: 36295013 Free PMC article.
-
Inferring human miRNA-disease associations via multiple kernel fusion on GCNII.Front Genet. 2022 Sep 5;13:980497. doi: 10.3389/fgene.2022.980497. eCollection 2022. Front Genet. 2022. PMID: 36134032 Free PMC article.
-
MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.Front Oncol. 2022 Apr 22;12:837581. doi: 10.3389/fonc.2022.837581. eCollection 2022. Front Oncol. 2022. PMID: 35530352 Free PMC article.
-
Plasma miR-323 as a Biomarker for Screening Papillary Thyroid Cancer From Healthy Controls.Front Med (Lausanne). 2020 May 15;7:122. doi: 10.3389/fmed.2020.00122. eCollection 2020. Front Med (Lausanne). 2020. PMID: 32478079 Free PMC article.
-
Association of MicroRNA Expression and BRAFV600E Mutation with Recurrence of Thyroid Cancer.Biomolecules. 2020 Apr 17;10(4):625. doi: 10.3390/biom10040625. Biomolecules. 2020. PMID: 32316638 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
